Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Immune Checkpoint Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06227728
What this trial is testing

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Who this might be right for
Non Small Cell Lung CancerBreast CancerColorectal Cancer+4 more
Gene Solutions 50
Not applicableLooking for participantsNCT07223411
What this trial is testing

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Who this might be right for
Locally Advanced Melanoma
John Kirkwood 20
Not applicableLooking for participantsNCT05867004
What this trial is testing

Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

Who this might be right for
MelanomaImmune DefectTumor Skin
Institut Claudius Regaud 100
Testing effectiveness (Phase 2)Ended earlyNCT03645928
What this trial is testing

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Who this might be right for
Metastatic MelanomaSquamous Cell Carcinoma of the Head and NeckNon-small Cell Lung Cancer
Iovance Biotherapeutics, Inc. 225
Not applicableNot Yet RecruitingNCT07527819
What this trial is testing

Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Peter MacCallum Cancer Centre, Australia 75
Testing effectiveness (Phase 2)Looking for participantsNCT06527898
What this trial is testing

Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer

Who this might be right for
Small-cell Lung Cancer
Anhui Provincial Hospital 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT05822752
What this trial is testing

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma
AbbVie 130
Not applicableStudy completedNCT04656873
What this trial is testing

Immuno-Oncology Database and Bioregistry

Who this might be right for
MalignancyImmune System DiseasesAutoimmune Diseases
UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Looking for participantsNCT06368141
What this trial is testing

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

Who this might be right for
Colon Cancer
Ruijin Hospital 56
Testing effectiveness (Phase 2)UnknownNCT05281003
What this trial is testing

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Fudan University 128
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07353827
What this trial is testing

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University 36
Not applicableUnknownNCT04492969
What this trial is testing

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Who this might be right for
NSCLC Stage IVNSCLC, Recurrent
Fudan University 320
Testing effectiveness (Phase 2)Ended earlyNCT05117242
What this trial is testing

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Genmab 125
Testing effectiveness (Phase 2)Looking for participantsNCT05779423
What this trial is testing

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Who this might be right for
Metastatic MelanomaSkin Cancer
Massachusetts General Hospital 37
Large-scale testing (Phase 3)Looking for participantsNCT06346197
What this trial is testing

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Who this might be right for
Gastric CancerMSI-HMetastatic Cancer+1 more
Centre Leon Berard 132
Not applicableNot Yet RecruitingNCT07665697
What this trial is testing

Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study

Who this might be right for
NeoplasmsDrug TherapyImmune Checkpoint Inhibitors (ICIs)
Sichuan University 500
Not applicableNot Yet RecruitingNCT07028008
What this trial is testing

Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

Who this might be right for
Melanoma
Samsung Medical Center 9
Early research (Phase 1)Study completedNCT02403193
What this trial is testing

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Palobiofarma SL 92
Large-scale testing (Phase 3)Not Yet RecruitingNCT07132008
What this trial is testing

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Who this might be right for
Colonic NeoplasmsNeoadjuvant TherapyImmune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University 94
Not applicableStudy completedNCT03305380
What this trial is testing

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Who this might be right for
Stage IV Non-small Cell Lung Cancer
Maastricht Radiation Oncology 637
Next Page